Clinical Trial Update: Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of vemurafenib and cobimetinib in patients with BRAF-mutated melanoma with brain metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Cobimetinib (cobimetinib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Center Eugene Marquis | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED